Teva's generic Adderall XR capsules are indicated for the treatment of attention deficit hyperactivity disorder (ADHD).
In August 2006, Teva's subsidiary Barr Pharmaceuticals entered into a licensing agreement with Shire as part of a settlement of patent litigation between the parties. Under this agreement, Shire granted the company the exclusive right to sell a generic version of Adderall XR capsules for 180 days from the date of commercial launch.
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index